Abstracts Archive - Page 791 of 2425 - ACR Meeting Abstracts

Abstract Number: 2045 • ACR Convergence 2020
Resident Memory T Cells in Synovial Tissue Mediate Arthritis Flares
Margaret Chang¹, Anais Levescot², Nathan Nelson-Maney², Rachel Blaustein², Kellen Winden¹, Allyn Morris³, Spoorthi Balu³, Alexandra Wactor², Ricardo Grieshaber-Bouyer⁴, Kevin Wei⁵, Lauren Henderson⁶, Rachael Clark³, Deepak Rao², Robert Fuhlbrigge⁷ and Peter Nigrovic⁸, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Boston Children's Hospital, Watertown, MA, ⁷University of Colorado, Denver, CO, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in local immune defense.…
Abstract Number: 2046 • ACR Convergence 2020
Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
Ye Cao¹, Joshua Keegan², Alessandra Zaccardelli², Gregory Keras³, Jennifer Seifert⁴, Elizabeth Bemis⁵, Marie Feser⁶, M Kristen Demoruelle⁷, Kevin D. Deane⁸, Jill Norris⁵, Michael Brenner⁹, James Lederer¹⁰, V Michael Holers⁶, Jeffrey Sparks¹¹ and Deepak Rao², ¹Brigham and Women’s Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ⁵Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁶Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁷University of Colorado, Denver, CO, ⁸2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰BWH Harvard Medical School, Boston, MA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The cyclic citrullinated peptide (CCP) autoantibody is a highly specific and predictive marker for the clinical diagnosis of RA. Elevation in CCP titers can be…
Abstract Number: 2047 • ACR Convergence 2020
Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas³, Karishma Rupani⁴, Gerald Watts⁵, Kevin Wei¹, Runci Wang⁴, Deepak Rao⁴, Accelerating Medicines Partnership (AMP) - RA/SLE⁶, Soumya Raychaudhuri² and Michael Brenner¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigam and Women's Hospital, Boston, ⁶., Boston
Background/Purpose: T cell-derived pro-inflammatory cytokines are major drivers of RA pathogenesis, and these cytokines have traditionally been attributed to CD4 T cells. However, single-cell RNA-sequencing…
Abstract Number: 2048 • ACR Convergence 2020
Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
Valerie Benard¹, Cynthia Farhat², Melissa Zarandi-Nowroozi², Madeleine Durand³, Christian Pagnoux⁴, Pierre Charles⁵, Xavier Puechal⁶, Loïc Guillevin⁷ and Jean-Paul Makhzoum¹, ¹Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Internal Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, ²Department of Medecine, University of Montreal, Montreal, QC, Canada, ³Department of Internal Medicine, Centre Hospitalier de l’Universite de Montreal (CHUM) and Centre de Recherche du Centre Hospitalier de l’Universite de Montreal (CRCHUM), Montreal, QC, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁷Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France
Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or…
Abstract Number: 2049 • ACR Convergence 2020
Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis
Rennie Rhee¹, Jiarui Lu¹, Kyle Bittinger², Antoine Sreih¹, Jung-Jin Lee³, Lisa Mattei³, Brendan Kelly⁴, Peter C. Grayson⁵, Hongzhe Lee⁴, Ronald Collman⁴ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Nasal bacteria have been linked to disease activity in granulomatosis with polyangiitis (GPA) with most studies focused on Staphylococcus aureus. Our previous study identified…
Abstract Number: 2050 • ACR Convergence 2020
Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate
Sebastian Klapa¹, Antje Müller², Andreas Koch³, Anja Kerstein-Staehle⁴, Wataru Kaehler³, Harald Heidecke⁵, Susanne Schinke⁶, Markus Huber-Lang⁷, Martin Nitschke⁸, Silke Pitann⁹, Christian Karsten¹⁰, Gabriela Riemekasten¹¹ and Peter Lamprecht², ¹University of Lübeck and Institute of Experimental Medicine, Christian-Albrechts-University of Kiel c/o German Naval Medical Institute, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Institute of Experimental Immunology, Christian-Albrechts-University Kiel, c/o German Naval Medical Institute, Kronshagen, Germany, ⁴University of Lübeck, Dept Rheumatology and Clinical Immunology, Luebeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany, ⁶University of Lübeck, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, ⁷Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany, ⁸Department of Internal Medicine I, Transplant Center, University of Lübeck, Luebeck, Germany, ⁹University of Lübeck, Department of Rheumatology and Clinical Immunology,, Luebeck, Germany, ¹⁰Institute of Systemic Inflammation Research, University of Lübeck, Luebeck, Germany, ¹¹University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany
Background/Purpose: Activation of the alternative and common terminal complement pathways has been shown in ANCA-associated vasculitis (AAV). Circulating titers of the anaphylatoxin C5a are increased…
Abstract Number: 2051 • ACR Convergence 2020
Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database
Michele Iudici¹, Christian Pagnoux², Delphine Courvoisier³, Pascal Cohen⁴, Mohamed Hamidou⁵, Achille Aouba⁶, François Lifermann⁷, Marc Ruivard⁸, Olivier Aumaitre⁹, Bernard Bonnotte¹⁰, Julien Campagne¹¹, Olivier Decaux¹², Eric Hachulla¹³, Alexandre Karras¹⁴, Chahéra Khouatra¹⁵, Noémie Jourde-Chiche¹⁶, Jean-François Viallard¹⁷, Pascal Godmer¹⁸, Claire Blanchard-Delaunay¹⁹, Alain Le Quellec²⁰, Thomas Quéméneur²¹, Claire de Moreuil²², Alexis Regent⁴, Benjamin Terrier⁴, Luc Mouthon⁴, Loïc Guillevin⁴ and Xavier Puechal⁴, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University and Geneva University Hospitals, Geneva, Switzerland, ²Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of rheumatology, Geneva University Hospitals, Geneva, Switzerland, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁵Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, ⁶Department of Internal Medicine, CHU Côte de Nacre, Caen, France, ⁷Department of Internal Medicine, CH Côte d’Argent, Dax, France, ⁸Department of Internal Medicine, CHU Estaing, Clermont Ferrand, France, ⁹Department of Internal Medicine, CHU Gabriel Montpied, Clermont Ferrand, France, ¹⁰CHU Dijon, Dijon, France, ¹¹Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ¹²CHU Rennes, Rennes, France, ¹³Department of Internal Medicine, CHRU, Lille Cedex, France, ¹⁴Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, ¹⁵Department of Respiratory Medicine, CHU Louis Pradel, Lyon, France, ¹⁶Department of Nephrology, CHU de la Conception, Marseille, France, ¹⁷Department of Internal Medicine, CHU Haut-Lévêque, Bordeaux, France, ¹⁸Department of Internal Medicine, CH Bretagne Atlantique, Vannes, France, ¹⁹Department of Internal Medicine, CH, Niort, France, ²⁰Department of Internal Medicine, CHU Saint Eloi, Montpellier, France, ²¹Department of Internal Medicine, CH, Valenciennes, France, ²²Department of Internal Medicine, CHU Cavale Blanche, Brest, France
Background/Purpose: The clinical picture at onset and evolution of localized forms of granulomatosis with polyangiitis (L-GPA) have already been investigated but, to our knowledge, have…
Abstract Number: 2052 • ACR Convergence 2020
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne² and Peter A. Merkel³, ¹University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ³Division of Rheumatology University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse…
Abstract Number: PP01 • ACR Convergence 2020
Impacting Change Through Facilitation and Advocacy for Lupus
Monica Watson¹, ¹Lupus Foundation of America, Darby, PA
Background/Purpose: My story started as one of disbelief in 2009 with my Lupus diagnosis. How could a woman in the prime of her career be…
Abstract Number: PP02 • ACR Convergence 2020
Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease
Ida Hakkarinen¹, ¹Vasculitis Patient-Powered Research Network (VPPRN) / Member, Vasculitis Foundation, Greenbelt, MD
Background/Purpose: For over two years, I experienced a variety of disparate symptoms including: joint aches, sinus congestion, shortness of breath and chronic cough. An episode…
Abstract Number: PP03 • ACR Convergence 2020
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
Nancy Linn¹, Catherine Bammert², David Bammert³ and Michael Linn⁴, ¹Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, ²MD Anderson, Houston, TX, ³Relapsing Polychondritis Foundation, Houston, TX, ⁴Relapsing Polychondritis Foundation, New York, NY
Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
Abstract Number: PP04 • ACR Convergence 2020
My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life
Tedi LaMere¹, Michael Linn² and David Bammert³, ¹Relapsing Polychondritis Foundation, Kalispell, MT, ²Relapsing Polychondritis Foundation, New York, NY, ³Relapsing Polychondritis Foundation, Houston, TX
Background/Purpose: I enjoyed being physically active my entire life – climbing mountains, hunting, and hiking. This drastically changed around 2012, when I noticed that I was…
Abstract Number: PP05 • ACR Convergence 2020
Coping Through Advocacy – My Story Living with Relapsing Polychondritis
Allegonda Imeson¹, ¹The Canadian Society for Relapsing Polychondritis, Stony Plain, AB, Canada
Background/Purpose: Becoming a mother was the most pivotal moment of my life. From early on, I instilled the importance of a physical, healthy lifestyle for my two…
Abstract Number: PP06 • ACR Convergence 2020
Only in My Dreams Can I Do the Things I Used to Do: Where There Is Research, There Is Hope
Dan Smith¹, Robert Smith¹ and Jillian Covault¹, ¹Canton, MI
Background/Purpose: In Mach 2020, I was diagnosed with relapsing polychondritis ("RP"), a multisystem, rheumatologic disease characterized by inflammation of cartilaginous structures including the ear, nose,…
Abstract Number: PP07 • ACR Convergence 2020
Improving Communication with My Physician Drastically Improved My Health
Whitney Carter¹, ¹Lupus and Allied Diseases Association, Inc., Pleasanton, CA
Background/Purpose: In 2011, at the age of 14, I was sent to the emergency room with a platelet count of 19. The hematologist diagnosed me…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].